{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Coagulation+Factor+VIIa+%28Recombinant%29&page=2",
    "query": {
      "intervention": "Coagulation Factor VIIa (Recombinant)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Coagulation+Factor+VIIa+%28Recombinant%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Coagulation+Factor+VIIa+%28Recombinant%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T01:27:20.549Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00127283",
      "title": "Recombinant Factor VIIa in Acute Intracerebral Haemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Intracerebral Haemorrhage"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 829,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127283"
    },
    {
      "nct_id": "NCT01561937",
      "title": "Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Haemostasis",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2007-01",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-25",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561937"
    },
    {
      "nct_id": "NCT04563520",
      "title": "SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        },
        {
          "name": "FEIBA",
          "type": "DRUG"
        },
        {
          "name": "rFVIIa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2026-09",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563520"
    },
    {
      "nct_id": "NCT07227246",
      "title": "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biological/Vaccine: Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Broderick, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 350,
      "start_date": "2025-05-06",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227246"
    },
    {
      "nct_id": "NCT07290634",
      "title": "Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Thromboembolus",
        "Massive Blood Transfusion; Thrombocytopenia",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "Number of Participants with massive blood transfusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Zeliha Alicikus",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2026-04-30",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07290634"
    },
    {
      "nct_id": "NCT04023019",
      "title": "Treatment of Hemophilia A Patients With FVIII Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Octanate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wilate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emicizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant factor VIIa (rFVIIa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated prothrombin complex concentrate (aPCC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-03-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04023019"
    },
    {
      "nct_id": "NCT00102037",
      "title": "Use of Activated Recombinant FVII in Spinal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Spinal Fusion"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2004-07",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 14,
      "location_summary": "Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00102037"
    },
    {
      "nct_id": "NCT07136857",
      "title": "Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glanzmann Thrombasthenia"
      ],
      "interventions": [
        {
          "name": "EPTACOG BETA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 6,
      "start_date": "2025-10-02",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07136857"
    },
    {
      "nct_id": "NCT03496883",
      "title": "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Recombinant Activated Factor VII (rFVIIa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Broderick, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 860,
      "start_date": "2021-12-03",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Baldwin Park, California + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03496883"
    },
    {
      "nct_id": "NCT02448680",
      "title": "A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A With Inhibitors",
        "Hemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "Coagulation FVIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "Up to 11 Years · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2015-12-07",
      "completion_date": "2017-08-30",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-10-05T01:27:20.549Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02448680"
    }
  ]
}